Real World Experience of Alpha-1 Antitrypsin in Treatment-Refractory Acute Graft Versus Host Disease: High Durable Response Rate

Key Points

• High durable response rate observed in treatment-refractory acute graft versus host disease patients.
• The response rate was reported to be over 70% among treated patients, demonstrating significant clinical benefits.
• Observational analysis provided insights into the effectiveness of alpha-1 antitrypsin for managing this condition.
• Results suggest potential for broader applications of alpha-1 antitrypsin in similar immunological disorders.